We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Test Detects Parasite Responsible for Trichomoniasis Infection In 15 Minutes

By LabMedica International staff writers
Posted on 27 Feb 2025

Trichomoniasis is one of the most prevalent sexually transmitted infections globally. More...

It is caused by the parasite Trichomonas vaginalis, which is often difficult to detect as the infection is frequently asymptomatic, making diagnosis and treatment challenging. Early detection is crucial, as untreated infections can lead to reproductive health issues, increase the likelihood of HIV transmission, and cause genital tract inflammation. In response to this challenge, researchers have developed a rapid, cost-effective, and easy-to-use test for detecting the parasite. The findings from this research were published in Sensors & Diagnostics.

The test, called ALFA (Aptamer-based Lateral Flow Assay), was developed by a team from Universitat Rovira i Virgili (Tarragona, Spain) using innovative DNA aptamer technology. Aptamers are short nucleic acid sequences that can bind highly specifically to target molecules. The test employs a dual aptamer system: one aptamer is immobilized on a nitrocellulose membrane as a capturer, and the other is linked to gold nanoparticles, which generate a visual detection signal. This design helps to reduce production costs and enhances the stability of the test. One of the key benefits of this test is its affordability, costing under one euro. This makes it a viable tool for use in public health initiatives and in countries with limited healthcare resources.

The researchers demonstrated that the test can detect very low concentrations of the parasite without being confused by other common vaginal microorganisms, ensuring its accuracy. Stability is another significant advantage, as the test components retain their effectiveness for up to a year at room temperature (22 ºC), eliminating the need for refrigeration or special packaging. This feature makes the test suitable for distribution in resource-limited areas. Furthermore, the test is straightforward to use, requiring only three simple steps from sample collection to result, which can be obtained in about 15 minutes. In initial trials using clinical samples, the results were consistent with those obtained through the traditional method of direct observation. The research team plans to continue expanding its approach to detect other pathogens in the future.

Related Links:
Universitat Rovira i Virgili


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.